Therapeutic Plasma Exchange Market Size, Share, Growth Report 2032

Industry Perspective:

The global therapeutic plasma exchange market size was worth USD 1,528.40 million in 2021 and is estimated to grow to USD 2306.60 million by 2028, with a compound annual growth rate (CAGR) of approximately 7.10 percent over the forecast period. The report analyzes the therapeutic plasma exchange market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the therapeutic plasma exchange market.

Request Free Sample

Therapeutic Plasma Exchange Market: Overview

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an endovascular blood technique used to separate that means removing pathogenic substances from clients' blood and replacing them with replacement fluid such as albumin solution or frequently fresh frozen plasma. These compounds include infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is used to treat various autoimmune conditions, renal disorders, hematological disorders, etc., and is anticipated to fuel market expansion. Plasma viscosity can be significantly reduced by therapeutic plasma exchange (TPE). As a result, it can enhance blood flow and improve patient outcomes in COVID-19-positive critically ill patients. It is used as a first- or second-line therapy for a variety of chronic disorders in both neurology and non-neurological situations.

The main factors contributing to the market's growth are the rising number of clients with inflammatory illnesses, hematological disorders, cardiovascular diseases, and the elderly population. The prevalence of neurological health issues has significantly increased among the elderly. The use of cutting-edge techniques like plasma exchange in treating neurological illnesses is also becoming more widely known. These elements are anticipated to create fantastic demand opportunities in the global therapeutic plasma exchange market.

COVID-19 Impact:

The Covid-19 outbreak has impacted the growth expectations for several industries and companies. Coronavirus-infected patients have had success with convalescent plasma treatment. Biologics, convalescent plasma, and antivirals have all been utilized with varying degrees of success. Acute respiratory distress syndrome, sepsis, and multi-organ failure are brought on by the severe "cytokine storm" driven epitheliopathy and micro thrombotic illness in COVID-19 patients. The only method known to reduce plasma viscosity directly and swiftly is therapeutic plasma exchange (TPE), suggesting that TPE may improve patient outcomes in critically ill Covid-19 patients by reducing plasma viscosity and consequently boosting blood flow.

Request Free Sample

Key Insights

• As per the analysis shared by our research analyst, the global therapeutic plasma exchange market value to grow at a CAGR of 7.10% over the forecast period.
• In terms of revenue, the global therapeutic plasma exchange market size was valued at around USD 1,528.40 million in 2021 and is projected to reach USD 2306.60 million, by 2028.
• The government's favorable reimbursement policies will increase the number of patients with autoimmune diseases, and this, combined with an increase in healthcare facility consolidation, will fuel market expansion.
• By end users, the hospitals category dominated the market in 2021.
• By disease indication, the neurological disorder category dominated the market in 2021.
• North America dominated the global therapeutic plasma exchange market in 2021.

Therapeutic Plasma Exchange Market: Growth Drivers

Therapeutic plasma exchange for pediatric patients to drive market growth

Therapeutic plasma exchange treatments are rarely used on pediatric patients. Although this therapeutic approach has several technical limitations in children, pediatric nephrology uses it more frequently. Market players may have opportunities for expansion due to the increased use of therapeutic plasma exchange to treat various disorders. Due to technological advancements, juvenile children with renal disorders undergo TPE operations, which has fueled the growth of the global therapeutic plasma exchange market.

Therapeutic Plasma Exchange Market: Restraints

High cost of for therapeutic plasma exchange products to hinder the market growth

The cost of equipment heavily influences the adoption of plasma exchange by medical professionals and, ultimately, patients. Blood banks employ apheresis equipment to collect blood components, and hospitals utilize it for therapeutic plasma exchange operations. The entire cost of apheresis treatments is also increased by the high cost of equipment and disposable items.

Therapeutic Plasma Exchange Market: Opportunity

Continuous advancement to present market growth opportunities

Constant advancement in technology has improved and become a high-precision method. It improves patient satisfaction and more effective processing of goods made from blood and plasma. Compared to other technologies, like membrane separation methods, this method needs a small amount of blood flow. It is a more advanced technique that simplifies getting blood through the patient's antecubital or radial veins. More precise hydration status control for greater hemodynamic stability during treatment and improved patient comfort and safety during the TPE operation are also outcomes of these technological advancements, generating profitable potential pockets in the market.

Therapeutic Plasma Exchange Market: Segmentation

The global therapeutic plasma exchange market has been segmented into end users, diseases indication, and region.

Based on end users, the market is classified into hospitals, specialty clinics, and ambulatory surgical centers. In 2021, the hospital's category dominated the global market. The segment is anticipated to increase at the fastest rate. The domination of the hospital sector is ascribed to an increase in autoimmune disorder sufferers and a growth in the number of patients using Medicare & other reimbursement systems. The hospital category is also driven by a surge in healthcare facility consolidation and an increase in doctors moving from private clinics to large-scale hospitals.

Based on disease indication, the global therapeutic plasma exchange market is segmented into neurological disorders, renal disorders, hematology disorders, and other disorders. The neurological disorder is anticipated to have the highest share in this market. The incidence and prevalence of neurological diseases are increasing in the geriatric population, knowledge & understanding of the use of plasma exchange in treating neurological diseases is rising, and key players are increasing their R&D expenditures on new applications for therapeutic plasma exchange in the management of neurological disorders. These factors are the main drivers of market growth.

Recent Developments

• April 2020: Terumo BCT and Marker Therapeutics received the first FDA emergency use authorization (EUA) device to treat COVID-19 patients with acute respiratory failure.
• May 2020 Ceros Corporation acquired FDA regulatory permission to manufacture INTERCEPT plasma using a novel, disposable plastic kit.
• December 2019: Haemon tics Corporation launched its new corporate headquarters in Downtown Boston.

Global Clean-In-Place Market: Report Scope:

To know more about this report, request a sample copy.

Therapeutic Plasma Exchange Market: Regional Landscape

North America dominated the therapeutic plasma exchange market in 2021

The dominance of North America in the global therapeutics plasma exchange market is brought on by a growth in the incidence of several autoimmune diseases global, a sharp increase in the use of lipoprotein apheresis therapy for cardiac diseases such as coronary artery disease (CAD), hypercholesterolemia strokes, and atherosclerosis, as well as a recent surge in the number of cardiac deaths. The demand for therapeutic plasma exchange treatments will be driven primarily by the high geriatric population and rising healthcare spending in this region over the next few years, which will undoubtedly accelerate the regional market expansion.

North America is anticipated to have the most revenue over the projected period due to established hospital infrastructure and top global companies. Their domination has been aided by the presence of numerous biotech enterprises, as well as academic and research institutions. The need for therapeutic plasma exchange treatments is also anticipated to increase over time due to the accelerated expansion of academic and research organizations in these fields.

Therapeutic Plasma Exchange Market: Competitive Landscape

Some of the main competitors dominating the global therapeutic plasma exchange market include- Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melungeon AG, Fresenius Kabir AG, Karasumi Laboratories, Inc., Haemon tics Corporation, Ceros Corporation, Hema care Corporation, and Medica S.p.A.

Global Therapeutic Plasma Exchange Market is segmented as follows:

By Diseases Indication

• Neurological Disorders
• Renal Disorders
• Hematology Disorders

By End-Users

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa